Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2005-09-28
2011-11-29
Li, Bao (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C424S232100
Reexamination Certificate
active
08067535
ABSTRACT:
The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Three vaccinia virus CD8+T cell epitopes restricted by the most common human M.C. class I allele, HLA-A0201, were identified. Each of these epitopes is highly conserved in vaccinia and variola viruses. In addition, the induction of the T cell responses following primary vaccination with two of these epitopes is demonstrated by the kinetics of epitope specific CD8+T cells in 3 HLA-A0201 individuals. Two vaccinia virus CD8+T cell epitopes restricted by another common human M.C. class I allele, HLA-B7, also were identified. Both epitopes are highly conserved in vaccinia and variola viruses. This information will be useful for the design and analysis of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.
REFERENCES:
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 5674502 (1997-10-01), Ennis
patent: 5766601 (1998-06-01), Ennis
patent: 5882650 (1999-03-01), Ennis
patent: 6232448 (2001-05-01), Yoshikubo et al.
patent: 6627407 (2003-09-01), Ennis
patent: 6962790 (2005-11-01), Ennis
patent: 7026443 (2006-04-01), Sette et al.
patent: 7217526 (2007-05-01), Terajima et al.
patent: 2004/0132132 (2004-07-01), Sahin et al.
patent: 2005/0129703 (2005-06-01), Ennis et al.
patent: 1 398 380 (2004-03-01), None
patent: WO 95/15764 (1995-06-01), None
patent: WO 95/24925 (1995-09-01), None
patent: WO 96/03144 (1996-02-01), None
patent: WO 97/45444 (1997-12-01), None
patent: WO 98/03192 (1998-01-01), None
patent: WO 99/02550 (1999-01-01), None
patent: WO00/24778 (2000-05-01), None
patent: WO 02/068682 (2002-09-01), None
patent: WO 2004/024756 (2004-03-01), None
patent: WO 2004/067032 (2004-08-01), None
patent: WO2006/0706003 (2006-07-01), None
Colman P. Research in Immunology, 1994, vol. 145, pp. 33-36.
Smilek et al. Proc. natl. Acad. Sci. USA, 1991, vol. 88, pp. 9633-9637.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 1982, vol. 79, pp. 1979-1983.
Ennis F et al. J. Infect. Dis. 2002, vol. 185, pp. 1657-1659.
Demkowicz et al. J. Virol. 1993, vol. 67, No. 3, pp. 1538-1544.
Lazar, E., et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Mol. Cell. Biol., 8(3): 1247-1252 (1988).
Skelton, N.J., et al., “Proton NMR Assignments and Solution Conformation of RANTES, a Chemokine of the C-C Type,”Biochemistry, 34: 5329-5342 (1995).
Smilek, D.E., et al., “A Single Amino Acid Change in a Myelin Basic Protein Peptide Confers the CapaCity to Prevent Rather Than Induce Experimental Autoimmune Encephalomyelitis,”Proc. Natl. Acad. Sci. USA, 88: 9633-9637 (1991).
Drexler, I., et al., “Identification of Vaccinia Virus Epitope-Specific HLA-A*0201-Restricted T Cells and Comparative Analysis of Smallpox Vaccines,”Proc. Natl. Acad. Sci. USA100(1):217-222 (Jan. 2003).
Terajima, M., et al., “Quantitation of CD8+T Cell Responses to Newly Identified HLA-A*0201-Restricted T Cell Epitopes Conserved Among Vaccinia and Variola (Smallpox) Viruses,”J. Exp. Med. 197(7):927-932 (Apr. 2003).
Ramirez, J.C., et al., “Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison With the Western Reserve Strain and Advantages as a Vaccine,”J. Virol. 74(2):923-933 (Jan. 2000).
Gen Bank Acc. No. M35027 “Vaccinia Virus, Complete Genome,” (1990, updated 2000).
Wagner, C., et al., “Identification of an HLA-A*02 Restricted Immunogenic Peptide Derived from the Cancer Testis Antigen HOM-MEL-40/SSX2,”Cancer Immunity3:18 (Dec. 2003).
Oseroff, C., et al., “HLA Class I-restricted Responses to Vaccinia Recognize a Broad Array of Proteins Mainly Involved in Virulence and Viral Gene Regulation,”Proc. Natl. Acad. Sci. USA102(39):13980-13985 (2005).
Carroll, M.W., et al., “Highly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: a Murine Tumor Model,”Vaccine15(4):387-394 (1997).
Carroll, M.W., and Moss, B., “Poxviruses as Expression Vectors,”Curr. Opin. Biotechnol. 8(5):573-577 (1997).
DeLisi, C., et al., “T-cell Antigenic Sites Tend to be Amphipathic Structures,”Proc. Natl. Acad. Sci. USA82:7048-7052 (1985).
Bixler, Jr., G.S., and Atassi, M.Z., “T Cell Recognition of Myoglobin. Localization of the Sites Stimulating T Cell Proliferative Responses by Synthetic Overlapping Peptides Encompassing the Entire Molecule,”J. Immunogenet. 11(5-6):339-353 (1984).
Geysen, H.M., et al., “The Delineation of Peptides Able to Mimic Assembled Epitopes,” inSynthetic as Antigens—Ciba Foundation Symposium119 (Porter, R., and Whelan, J., Eds.), pp. 130-149, John Wiley & Sons, Chichester (1986).
Mathew, A., et al., “Identification of Murine Poxvirus-specific CD8+. CTL Epitopes with Distinct Functional Profiles,”J. Immunol. 174:2212-2219 (2005).
Tscharke, D.C., et al., “Identification of Poxvirus CD8+T Cell Determinants to Enable Rational Design and Characterization of Smallpox Vaccines,”J. Exp. Med. 201(1):95-104 (2005).
Gen Bank Acc. No. Y16780, “Variola Minor Virus Complete Genome,” (updated 2005), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. X69198, “Variola Virus DNA Complete Genome,” (updated 2005), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. L22579, “Variola Major Virus (Strain Bangladesh—1995) Complete Genome,” (1995), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. AF095689, “Vaccinia Virus (Strain Tian Tan) Complete Genome,” (2000), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. M35027, “Vaccinia Virus Complete Genome,” (1993), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. U94848, “Vaccinia Virus Strain Ankara, Complete Genomic Sequence,” (2003), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. AF482758, “Cowpox Virus Strain Brighton Red, Complete Genome,” (2003), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. AF380138, “Monkeypox Virus Strain Zaire-96-I-16, Complete Genome,” (2001), [online][retrieved on Nov. 14, 2005].
Gen Bank Acc. No. X94355, “Cowpox Virus Strain GRI-90, Complete Genome,” (2005), [online][retrieved on Nov. 14, 2005].
Bixler, G.S. and Atassi, M.Z., “Molecular Localization of the Full Profile of the Continuous Regions Recognized by Myoglobin Primed T-Cells Using Synthetic Overlapping Peptides Encompassing the Entire Molecule,”Immunological Communications12(6):593-603 (1983).
Feb. 27, 2009, Final Office Action, 11 pages, U.S. Appl. No. 11/731,784.
Dec. 10, 2008, Amendment, U.S. Appl. No. 11/731,784.
May 1, 2009, Amendment after Final Rejection, U.S. Appl. No. 11/731,784.
Jun. 10, 2009, Examiner Interview Summary Record (PTOL-413), U.S. Appl. No. 11/731,784.
Jun. 18, 2009, Advisory Action (PTOL-303), U.S. Appl. No. 11/731,784.
Jun. 24, 2009, Examiner Interview Summary Record (PTOL-413), U.S. Appl. No. 11/731,784.
Aug. 21, 2009, Supplemental Response, U.S. Appl. No. 11/731,784.
Dec. 12, 2009, Examiner Interview Summary Record (PTOL-413), U.S. Appl. No. 11/731,784.
Feb. 26, 2010, Amendment, U.S. Appl. No. 11/731,784.
Apr. 30, 2010, Examiner Interview Summary Record (PTOL-413), U.S. Appl. No. 11/731,784.
Apr. 30, 2010, Notice of Allowance, U.S. Appl. No. 11/731,784.
Aug. 11, 2005, Notification Concerning Transmittal of International Preliminary Report on Patentability and International Preliminary Report on Patentability, PCT/US2004/002141.
Nov. 11, 2009, Result of Consultation by telephone with the applicant / representative, EP 04 705 315.2.
Dec. 4, 2009, Letter accompanying subsequently filed items and matter concerning the application, EP 04 705 315.2.
Jan. 19, 2010, Communication pursuant to Article 94(3) EPC, EP 04 705
Cruz John
Ennis Francis A.
Terajima Masanori
Hamilton Brook Smith & Reynolds P.C.
Li Bao
The University of Massachusetts
LandOfFree
Identification of gene sequences and proteins involved in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of gene sequences and proteins involved in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of gene sequences and proteins involved in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262004